Pyrilutamide is being developed by Kintor Pharmaceutical for the treatment of androgenic alopecia in males. Kintor Pharmaceutical is a clinical stage biotechnology company focusing on discovering small molecules therapeutics targeting cancer and other androgen receptor related diseases.
Pure Pyrilutamide (KX-826) solution in a propylene glycol and ethanol vehicle. Each batch is tested by a 3rd party to ensure >99% purity.
What is Pyrilutamide?
Buy pyrilutamide Europe (development code KX-826) is a topical androgen receptor antagonist. It is being developed by Kintor Pharmaceutical of China to be used for hair loss. It has shown promising results in clinical trials. It is expected to be more effective than oral 5-alpha reductase inhibitors because it does not decrease systemic androgen levels.
The drug has completed phase 2 trials in China and the US. The data from the trial should be available this fall and should provide some important clues as to how useful pyrilutamide might be for hair loss.
The drug is being developed by Kintor Pharmaceutical, a clinical stage company that is focused on androgen receptor-related diseases with unmet medical needs. It has several drug candidates in development, including Proxalutamide, GT20029 and others. For more information about Kintor, please visit their website.
How is Pyrilutamide made?
Buy pyrilutamide in Europe, also known as KX-826, is a chemical developed by Kintor Pharmaceuticals for the treatment of androgen-dependent hair loss. It is in clinical trials for both male and female androgenetic alopecia (pattern hair loss) in China and the United States. It has a similar structure to RU58841 and both have a high affinity for androgen receptors.
It has been shown in clinical trials to be effective in treating alopecia. However, it does not appear to be as effective as oral 5-alpha reductase inhibitors. In addition, it does not cause the unwanted side effects of these drugs such as decreased libido or erectile dysfunction.
Kintor Pharmaceuticals announced today that their drug pyrilutamide has entered phase 3 clinical trials in the US for androgenetic alopecia. This trial will be a randomized, double-blind, placebo-controlled, multi-regional study with a sample size of 416 participants. The company will begin the phase 3 trial this year (2021). To see how Pyrilutamide ranks in comparison to other drugs in the same stage of development, buy GlobalData’s Pyrilutamide LoA Report.
Where can I buy Pyrilutamide?
Pyrilutamide (KX-826) is a novel anti-androgen developed by Kintor Pharmaceuticals. It blocks testosterone and dihydrotestosterone (DHT) from binding to androgen receptors in the follicle, which is the key cause of hair loss. It is currently in phase II clinical trials for androgenic alopecia. The trials are conducted by Suzhou Kintor Pharmaceuticals and are expected to be completed in 2022.
The raw material pyrilutamide (KX-826) used in PyriPure is >99% pure and every batch of the finished product is tested by a professional lab to ensure that it meets the purity standards. The 0.5% pyrilutamide solution is then delivered to you in an air and light tight bottle with a calibrated dropper for easy usage.
To learn more about Pyrilutamide and its current status in clinical development, buy our Pyrilutamide LoA Report. GlobalData creates drug-specific PTSR and LoA scores using proprietary data and insights built off of 18 years of historical drug development data.
What is the cost of Pyrilutamide?
Pyrilutamide is an androgen receptor antagonist being developed as a topical treatment for androgenic alopecia. It is being manufactured by Kintor Pharmaceutical Limited and has completed phase II clinical trials in the US and China. Kintor Pharmaceutical Ltd has also announced that they are conducting a larger scale, phase III trial of KX-826 in 2022.
The phase III trial will be conducted in both male and female patients with androgenetic alopecia. It will measure the change in non-vellus target area hair count and will be conducted over 24 weeks across multiple sites.
The company has also indicated that the phase 2 data from the US and Chinese trials will be used to support a phase 3 trial next year (2021). GlobalData tracks drug-specific PTSR and LoA by indication using 18 years of historical drug development benchmarks and includes key attributes such as company, drug development stage, phase transition probability and likelihood of approval. Get a copy of our Pyrilutamide LoA report here.